Context Therapeutics (NASDAQ:CNTX) Upgraded at Citizens Jmp

Citizens Jmp upgraded shares of Context Therapeutics (NASDAQ:CNTX) to a strong-buy rating in a research note issued to investors on Wednesday,Zacks.com reports.

Other research analysts have also issued reports about the company. JMP Securities started coverage on Context Therapeutics in a research report on Wednesday. They issued an “outperform” rating and a $4.00 price objective on the stock. D. Boral Capital initiated coverage on Context Therapeutics in a research report on Monday, November 25th. They set a “buy” rating and a $9.00 price target on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Context Therapeutics in a research report on Monday, September 23rd. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Context Therapeutics currently has a consensus rating of “Buy” and an average price target of $6.33.

Context Therapeutics Stock Performance

Shares of NASDAQ CNTX opened at $1.08 on Wednesday. The firm has a market cap of $81.00 million, a P/E ratio of -1.19 and a beta of 2.10. Context Therapeutics has a 1 year low of $0.89 and a 1 year high of $2.75. The firm’s 50 day moving average price is $1.47 and its 200 day moving average price is $1.92.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.11). As a group, equities analysts predict that Context Therapeutics will post -0.51 EPS for the current year.

Institutional Trading of Context Therapeutics

Several institutional investors have recently modified their holdings of the company. Great Point Partners LLC acquired a new stake in shares of Context Therapeutics during the 2nd quarter valued at $14,876,000. Blue Owl Capital Holdings LP acquired a new position in shares of Context Therapeutics in the 2nd quarter valued at $10,348,000. Driehaus Capital Management LLC purchased a new position in Context Therapeutics in the 2nd quarter worth about $4,527,000. Nantahala Capital Management LLC acquired a new stake in Context Therapeutics during the 2nd quarter worth about $3,881,000. Finally, Franklin Resources Inc. purchased a new stake in Context Therapeutics during the third quarter valued at about $3,689,000. Institutional investors and hedge funds own 14.03% of the company’s stock.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.